Melanotan-2 Tan & Libido Duality
A synthetic α-melanocyte-stimulating hormone analogue with dual pigmentation and central libido effects.
Book Free ConsultationCall 310.299.4444What Melanotan-2 actually is
Melanotan-2 is a synthetic cyclic heptapeptide analogue of α-melanocyte-stimulating hormone, developed at the University of Arizona in the 1980s.1 It is a non-selective agonist of melanocortin receptors — MC1R (skin pigmentation), MC3R/MC4R (sexual function, appetite). The therapeutic interest is the dual pigmentation and central libido effect that flows from melanocortin engagement.
Unlike afamelanotide (Scenesse, FDA-approved for erythropoietic protoporphyria), Melanotan-2 is not approved for cosmetic use. The related bremelanotide (PT-141) was FDA-approved as Vyleesi for HSDD in 2019 and shares the central libido mechanism.2
At Luxbae, Melanotan-2 is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.
Mechanism — Melanocortin receptor agonism
Activates MC1R on melanocytes (eumelanin synthesis) and MC3R/MC4R in CNS (appetite suppression, central libido).1
What the research shows
Pigmentation response. Increased melanocyte eumelanin output produces a tanned appearance with less UV exposure than baseline.1
Central libido pathway. MC4R engagement contributes to libido — the same pathway exploited by FDA-approved bremelanotide.2
Appetite modulation. Transient mild appetite suppression consistent with MC4R biology.
Side effects: Nausea (especially first doses), facial flushing, transient BP changes, darkening of existing moles, occasional spontaneous erections in male patients.
FDA note: Not FDA-approved for cosmetic or libido use. PT-141 is FDA-approved for HSDD; afamelanotide is approved for EPP.
Melanotan-2 FAQ
Will it darken my moles?
Often yes. We screen mole burden first; atypical nevi or melanoma history disqualify.
How does it differ from PT-141?
PT-141 targets MC4R primarily and is FDA-approved for libido. Melanotan-2 is non-selective and also acts on MC1R for pigmentation.
References
- Dorr RT, Lines R, Levine N, et al. Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide. Life Sci. 1996;58(20):1777-1784.
- Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for HSDD. Obstet Gynecol. 2019;134(5):899-908.
- Wessells H, Levine N, Hadley ME, et al. Melanocortin receptor agonists, penile erection, and sexual motivation. Int J Impot Res. 2000;12 Suppl 4:S74-79.